Systematizing PDE4 Inhibition in Psoriasis Treatment: Roflumilast Leads the Way

Psoriasis, a prevalent autoimmune disorder, presents significant challenges due to its chronic inflammatory nature and multifactorial etiology, involving both genetic tendency and environmental factors. Conventional therapies, while providing symptomatic relief, often stay behind to achieve sustained remission. This review explores advancements in psoriasis treatment, emphasizing the emergence of targeted therapies and biologics as the priority in enhancing disease management. Focus is on plaque psoriasis, the most common clinical subtype and the role of Roflumilast, a Phosphodiesterase-4 (PDE4) inhibitor, in modern therapeutic approaches. Roflumilast exerts immunomodulatory effects by increasing intracellular cyclic Adenosine Monophosphate (cAMP), which attenuates inflammation and keratinocyte hyperproliferation, key pathological features of psoriasis. A comprehensive literature review was conducted using scholarly databases and clinical trial registries. Key terms such as “Psoriasis treatment,” “PDE4 inhibitors,” “Roflumilast,” “Targeted therapy,” and “Therapeutic efficacy” guided the search. Priority was given to randomized controlled trials, observational studies and meta-analyses to ensure robust data inclusion. Clinical evidence suggests that Roflumilast exhibits a favorable safety profile compared to conventional treatments. Highlighting findings include rapid clinical improvement, patients achieving clear or almost clear skin within weeks and fewer adverse effects, indicating its efficacy and tolerability. This review brings to light Roflumilast’s potential to revolutionize psoriasis treatment, offering improved outcomes and safety. While additional research is inevitable to establish its long-term safety profile, Roflumilast represents a promising step forward in enhancing patient quality of life and reshaping psoriasis management.